💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cefmenoxime Hydrochloride

CHEMBL3183193 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1059.6 g/mol
LogP
—
Phase
4

The hydrochloride salt form of cefmenoxime, administered parenterally for the treatment of serious gram-negative bacterial infections. It shares the broad-spectrum cephalosporin antibacterial activity of the parent compound. Clinical use requires awareness of potential coagulation-related side effects associated with its N-methylthiotetrazole moiety.

Peso Molecular

1059,6000 g/mol

TPSA

539,00 Ų

Mecanismo de Ação

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1.CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/2C16H17N9O5S3.ClH/c2*1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7;/h2*5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29);1H/b2*21-8-;/t2*9-,13-;/m11./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C32H35ClN18O10S6

                    

                    
                    

                        
HBD / HBA

                        
7 / 28

                    

                    
                    

                        
Ligações Rotacionáveis

                        
16

                    

                    
                    
                    

                        
Átomos Pesados

                        
67

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
The hydrochloride salt form of cefmenoxime, administered parenterally for the treatment of serious gram-negative bacterial infections. It shares the broad-spectrum cephalosporin antibacterial activity of the parent compound. Clinical use requires awareness of potential coagulation-related side effects associated with its N-methylthiotetrazole moiety.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cefmenoxime Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3183193.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11954009.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.